Which treatment option is generally accepted care for managing COPD?

In the management of chronic obstructive pulmonary disease (COPD), combination therapy with inhaled corticosteroids and long-acting beta-agonists, such as fluticasone and salmeterol, is widely recognized as an effective treatment option. This combination addresses both inflammation and bronchoconstriction, which are key components of COPD. The corticosteroid component helps reduce airway inflammation, while the long-acting bronchodilator helps to keep the airways open, improving airflow and breathing capacity for patients.

Using this combination therapy can significantly improve symptoms, enhance the quality of life, and reduce exacerbations in patients with moderate to severe COPD. This approach is based on evidence from various clinical guidelines and trials that demonstrate its effectiveness in managing the conditions associated with COPD.

On the other hand, short-acting bronchodilators are typically used for immediate relief of symptoms rather than for long-term management. Oral corticosteroids are not generally used for long-term management of COPD due to their side effects and are typically reserved for acute exacerbations. Intravenous antibiotics are specifically aimed at treating infections and are not a standard treatment for managing COPD itself.